

Liangce Rong,* Hongxia Han, Haiying Wang, Hong Jiang, Shuaijiang Tu, and Daqing Shi


Department of Chemistry, Xuzhou Normal University, Key Laboratory of Biotechnology for Medicinal Plant, Xuzhou, Jiangsu, 221116, People's Republic of China

*E-mail: lcrong2005@yahoo.com

Received September 19, 2007

DOI 10.1002/jhet.43

Published online 16 March 2009 in Wiley InterScience (www.interscience.wiley.com).



An efficient and convenient method for the preparation of pyrimidine and quinazoline derivatives by the one-pot reaction of aromatic aldehydes, cyclic ketones and guanidine carbonate, in the presence of sodium hydroxide under solvent-free condition was reported. This method has the advantages of excellent yields, mild reaction conditions, easy work-up, and being environmentally friendly over the existing procedures.

J. Heterocyclic Chem., **46**, 152 (2009).

INTRODUCTION

Pyrimidine and its derivatives, as the nitrogen-containing heterocycles, are extremely important compounds with high biological activities [1]. The quinazoline nucleus is also a very attractive and useful scaffold in medicinal chemistry: it can be found as a pharmacophore in a wide variety of biologically active compounds, such as antitumorals [2], antibacterials [3], anti-virals [4], and many other therapeutic agents [5].

In recent years, because of increasing environmental concerns and the regulatory constraints faced in the chemical and pharmaceutical industries, the development of environmentally friendly organic synthesis has become a crucial and demanding area in modern organic chemical research [6]. In order to avoid using organic solvents, solvent-free organic reactions [7], a “green” organic chemistry method, have been of great interest. These have many advantages such as high efficiency and selectivity, easy separation and purification, mild reaction conditions, and reduction in waste produced. Many organic reactions have been carried out just by heating [8].


In continuation to our current studies on the application of solvent-free conditions for the synthesis of or-

ganic compounds [9], herein, we would like to report a practical and simple method to prepare pyrimidine and quinazoline derivatives by heating the starting materials under dry conditions.

RESULTS AND DISCUSSION

At first, cyclohexanone (2 mmol), aromatic aldehyde (4 mmol), guanidine carbonate (1 mmol) and NaOH (0.2 g) were chosen to react together under solvent-free conditions at 70°C, and the reaction proceeded smoothly in short time (about 15 min) and the corresponding compounds 4-aryl-8-arylidene)-5,6,7,8-tetrahydroquinazolin-2-amine (**4a–4h**) could be gained with high yields (Scheme 1). Then, the reagent of 3,4-dihydronaphthalen-1(2H)-one (2 mmol) was chosen to replace cyclohexanone to react with aromatic aldehyde (2 mmol), guanidine carbonate (1 mmol) under the same conditions, and the corresponding fused-ring quinazoline derivatives: *viz.* 4-(4-bromophenyl)-5,6-dihydrobenzo[*h*]quinazolin-2-amine (**6a–6h**), were obtained with excellent yields. The results of reactions were listed in Table 1. As shown in Table 1, all the reactions proceeded smoothly with high yields. We also observed that electron-

Scheme 1




withdrawing substituents ($-\text{Cl}$, $-\text{Br}$), and electron-donating substituents ($-\text{CH}_3$, $-\text{OCH}_3$) had no effect on the reaction.

In order to apply this reaction to a library synthesis, cyclopentanone and indan-1-one were chosen to react with aromatic aldehyde, and guanidine carbonate under same reaction conditions (Scheme 2). To our delight, all reactions could be completed successfully, and (*E*)-7-arylidene)-4-aryl-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-2-amine (**8a–8f**) and 4-aryl-5*H*-indenol[1,2-*d*]pyrimidin-2-amine (**10a–10g**) could be gained with good yields. The reaction results are summarized in Table 2. The structures of **4**, **6**, **8**, and **10** were confirmed by ir, ^1H NMR and elemental analysis, furthermore, the reported products were identified by comparison of melting point with those described in the literatures [10].

Although similar compounds have been reported in the literature and the disadvantages of reported methods were obvious, such as long reaction time, lower product yields and harsh conditions, furthermore, the excess of organic solvent was requisite.

In conclusion, an efficient method for the synthesis of pyrimidine and quinazoline derivatives by condensation

Scheme 2



of cyclic ketone, aromatic aldehydes, and guanidine carbonate was successfully established under solvent-free condition catalyzed by NaOH. The advantages of this procedure are high yields, mild reaction conditions, easy work-up, and environmentally friendly procedure.

EXPERIMENTAL

Melting points were determined on XT-5 microscopic melting-point apparatus and were uncorrected. IR spectra were recorded on a FT Bruker Tensor 27 spectrometer. ^1H NMR spectra were obtained from solution in DMSO-d_6 with Me_4Si as internal standard using a Bruker-400 spectrometer. Microanalyses were carried out using a Perkin-Elmer 2400 II analyzer.

General procedure for the synthesis of pyrimidine and quinazoline derivatives. The mixture of ketones **3** and **7**, or **5** and **9** (2 mmol), aromatic aldehydes **2** (4 mmol or 2 mmol), guanidine carbonate **3** (1 mmol) and NaOH (0.2 g) was put in a reaction flask and heated at 70°C for about 15 min. After completing the reaction, the reaction mixture was poured into water, and then washed with water thoroughly. The product was filtered, dried, and recrystallized from 95% ethanol.

(E)-8-(4-Methylbenzylidene)-4-*p*-tolyl-5,6,7,8-tetrahydroquinazolin-2-amine (4a). This compound was obtained as yellow crystals, mp 210–212°C, Lit. [10d] 210–212°C; ir (KBr, ν , cm^{-1}): 3502, 3282, 3152, 2929, 1626, 1541, 1456, 1220; ^1H NMR (400 MHz, DMSO-d_6) (δ , ppm): 8.00 (1H, s, ArCH=),

Table 1

Synthesis of quinazoline derivatives under solvent-free conditions.

Entry	Ar ¹	Product	Yields
1	4-CH ₃ C ₆ H ₄	4a	90
2	4-CH ₃ OC ₆ H ₄	4b	95
3	3,4-(CH ₃) ₂ C ₆ H ₃	4c	96
4	3,4-(CH ₃ O) ₂ C ₆ H ₃	4d	94
5	4-BrC ₆ H ₄	4e	92
6	4-ClC ₆ H ₄	4f	97
7	3-ClC ₆ H ₄	4g	90
8	3,4-Cl ₂ C ₆ H ₃	4h	95
9	4-CH ₃ C ₆ H ₄	6a	96
10	4-CH ₃ OC ₆ H ₄	6b	97
11	3,4-(CH ₃ O) ₂ C ₆ H ₃	6c	96
12	4-FC ₆ H ₄	6d	96
13	4-BrC ₆ H ₄	6e	98
14	4-ClC ₆ H ₄	6f	97
15	3,4-Cl ₂ C ₆ H ₃	6g	93
16	C ₆ H ₅	6h	95

Table 2

Synthesis of pyrimidine derivatives under solvent-free conditions.

Entry	Ar ¹	Product	Yields
1	4-CH ₃ C ₆ H ₄	8a	93
2	4-CH ₃ OC ₆ H ₄	8b	92
3	4-FC ₆ H ₄	8c	90
4	4-ClC ₆ H ₄	8d	93
5	3-ClC ₆ H ₄	8e	90
6	4-BrC ₆ H ₄	8f	95
7	4-CH ₃ C ₆ H ₄	10a	93
8	4-CH ₃ OC ₆ H ₄	10b	92
9	3,4-(CH ₃ O) ₂ C ₆ H ₃	10c	93
10	4-FC ₆ H ₄	10d	90
11	4-ClC ₆ H ₄	10e	93
12	4-BrC ₆ H ₄	10f	90
13	3,4-Cl ₂ C ₆ H ₃	10g	95

7.45 (2H, d, $J = 7.2$ Hz, ArH), 7.36 (2H, d, $J = 8.0$ Hz, ArH), 7.26 (4H, t, $J = 8.8$ Hz, ArH), 6.33 (2H, s, NH₂), 2.78 (2H, t, $J = 5.2$ Hz, CH₂), 2.60 (2H, t, $J = 5.2$ Hz, CH₂), 2.37 (3H, s, CH₃), 2.34 (3H, s, CH₃), 1.63 (2H, t, $J = 5.2$ Hz, CH₂). Anal. Calcd. For C₂₃H₂₃N₃: C 80.90, H 6.79, N 12.31. Found: C 80.72, H 6.73, N 12.25.

(E)-8-(4-Methoxybenzylidene)-4-(4-methoxyphenyl)-5,6,7,8-tetrahydroquinazolin-2-amine (4b). This compound was obtained as yellow crystals, mp 230–232°C, Lit. [10d] 245–247°C; ir (KBr, v, cm⁻¹): 3482, 3377, 3202, 2934, 1606, 1579, 1538, 1509, 1447, 1406, 1356, 1333, 1298, 1247; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.98 (1H, s, ArCH=), 7.53 (2H, d, $J = 8.4$ Hz, ArH), 7.42 (2H, d, $J = 8.4$ Hz, ArH), 7.01 (4H, dd, $J = 6.0$ Hz, J = 6.0 Hz, ArH), 6.28 (2H, s, NH₂), 3.81 (3H, s, OCH₃), 2.80 (3H, s, OCH₃), 2.79 (2H, t, $J = 5.6$ Hz, CH₂), 2.64 (2H, t, $J = 5.6$ Hz, CH₂), 1.62 (2H, t, $J = 5.2$ Hz, CH₂). Anal. Calcd. For C₂₃H₂₃N₃O₂: C 73.97, H 6.21, N 11.25. Found: C 73.78, H 6.27, N 11.31.

(E)-8-(3,4-Dimethylbenzylidene)-4-(3,4-dimethylphenyl)-5,6,7,8-tetrahydroquinazolin-2-amine (4c). This compound was obtained as yellow crystals, mp 191–193°C; ir (KBr, v, cm⁻¹): 3494, 3284, 3155, 2921, 1625, 1540, 1503, 1459, 1359, 1335, 1221; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.98 (1H, s, ArCH=), 7.33 (1H, s, ArH), 7.25 (3H, m, ArH), 7.19 (2H, t, $J = 8.8$ Hz, ArH), 6.30 (2H, s, NH₂), 2.80 (2H, t, $J = 5.2$ Hz, CH₂), 2.61 (2H, t, $J = 5.2$ Hz, CH₂), 2.28 (6H, s, 2CH₃), 2.27 (3H, s, CH₃), 2.25 (3H, s, CH₃), 1.61 (2H, t, $J = 5.2$ Hz, CH₂). Anal. Calcd. For C₂₅H₂₇N₃: C 81.26, H 7.37, N 11.37. Found: C 81.51, H 7.35, N 11.40.

(E)-8-(3,4-Dimethoxybenzylidene)-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroquinazolin-2-amine (4d). This compound was obtained as yellow crystals, mp 249–251°C, Lit. [10d] 231–233°C; ir (KBr, v, cm⁻¹): 3484, 3280, 3154, 3074, 2936, 1619, 1541, 1459, 1260, 1234; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.99 (1H, s, ArCH=), 7.11–7.15 (2H, m, ArH), 7.03 (4H, dd, $J = 8.0$ Hz, J = 8.0 Hz, ArH), 6.28 (2H, s, NH₂), 3.81 (3H, s, OCH₃), 3.80 (3H, s, OCH₃), 3.79 (3H, s, OCH₃), 3.77 (3H, s, OCH₃), 2.84 (2H, t, $J = 5.2$ Hz, CH₂), 2.65 (2H, t, $J = 5.2$ Hz, CH₂), 1.63 (2H, t, $J = 5.2$ Hz, CH₂). Anal. Calcd. For C₂₅H₂₇N₃O₄: C 69.27, H 6.28, N 9.69. Found: C 69.08, H 6.35, N 9.61.

(E)-8-(4-Bromobenzylidene)-4-(4-bromophenyl)-5,6,7,8-tetrahydroquinazolin-2-amine (4e). This compound was obtained as yellow crystals, mp 211–213°C; ir (KBr, v, cm⁻¹): 3488, 3287, 3157, 2934, 1625, 1591, 1540, 1486, 1456, 1332, 1231; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.98 (1H, s, ArCH=), 7.67 (2H, d, $J = 8.4$ Hz, ArH), 7.62 (2H, d, $J = 8.4$ Hz, ArH), 7.52 (2H, d, $J = 8.4$ Hz, ArH), 7.41 (2H, d, $J = 8.4$ Hz, ArH), 6.45 (2H, s, NH₂), 2.77 (2H, t, $J = 5.2$ Hz, CH₂), 2.60 (2H, t, $J = 6.0$ Hz, CH₂), 1.63 (2H, t, $J = 5.2$ Hz, CH₂). Anal. Calcd. For C₂₁H₁₇Br₂N₃: C 53.53, H 3.64, N 8.92. Found: C 53.33, H 3.62, N 8.96.

(E)-8-(4-Chlorobenzylidene)-4-(4-chlorophenyl)-5,6,7,8-tetrahydroquinazolin-2-amine (4f). This compound was obtained as yellow crystals, mp 195–197°C, Lit. [10d] 224–226°C; ir (KBr, v, cm⁻¹): 3497, 3319, 3202, 2939, 1631, 1606, 1543, 1507, 1464, 1417, 1357, 1333, 1317, 1224; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.01 (1H, s, ArCH=), 7.61 (2H, dd, $J = 6.0$ Hz, J = 6.0 Hz, ArH), 7.51 (2H, dd, $J = 6.0$ Hz, J = 6.0 Hz, ArH), 7.28 (4H, q, $J = 8.8$ Hz, $J = 6.4$

Hz, ArH), 6.41 (2H, s, NH₂), 2.78 (2H, br, CH₂), 2.60 (2H, t, $J = 5.2$ Hz, J = 5.2 Hz, CH₂), 1.63 (2H, t, $J = 5.2$ Hz, J = 5.2 Hz, CH₂). Anal. Calcd. For C₂₁H₁₇Cl₂N₃: C 65.98, H 4.48, N 10.99. Found: C 65.72, H 4.55, N 10.68.

(E)-8-(3-Chlorobenzylidene)-4-(3-chlorophenyl)-5,6,7,8-tetrahydroquinazolin-2-amine (4g). This compound was obtained as yellow crystals, mp 237–238°C; ir (KBr, v, cm⁻¹): 3484, 3285, 3157, 3078, 2932, 1624, 1592, 1543, 1461, 1436, 1411, 1351, 1334, 1268, 1219; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.98 (1H, s, ArCH=), 7.60 (1H, s, ArH), 7.38–7.54 (7H, m, ArH), 6.48 (2H, s, NH₂), 2.78 (2H, t, $J = 5.2$ Hz, CH₂), 2.61 (2H, t, $J = 6.0$ Hz, CH₂), 1.63 (2H, t, $J = 5.2$ Hz, CH₂). Anal. Calcd. For C₂₁H₁₇Cl₂N₃: C 65.98, H 4.48, N 10.99. Found: C 65.80, H 4.50, N 10.95.

(E)-8-(3,4-Dichlorobenzylidene)-4-(3,4-dichlorophenyl)-5,6,7,8-tetrahydroquinazolin-2-amine (4h). This compound was obtained as yellow crystals, mp 200–202°C; ir (KBr, v, cm⁻¹): 3479, 3296, 3184, 1625, 1541, 1472, 1415, 1389, 1351, 1331, 1215; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.95 (1H, s, ArCH=), 7.82 (1H, s, ArH), 7.74 (1H, $J = 8.4$ Hz, ArH), 7.68 (2H, $J = 8.4$ Hz, ArH), 7.57 (1H, $J = 8.4$ Hz, ArH), 7.44 (1H, $J = 8.4$ Hz, ArH) 6.53 (2H, s, NH₂), 2.77 (2H, t, $J = 5.2$ Hz, J = 5.2 Hz, CH₂), 2.61 (2H, t, $J = 6.0$ Hz, J = 6.0 Hz, CH₂), 1.63 (2H, t, $J = 5.2$ Hz, J = 5.2 Hz, CH₂). Anal. Calcd. For C₂₁H₁₅Cl₄N₃: C 55.90, H 3.35, N 9.31. Found: C 55.78, H 3.34, N 9.34.

4-p-Tolyl-5,6-dihydrobenzo[h]quinazolin-2-amine (6a). This compound was obtained as yellow crystals, mp 192–194°C, Lit. [10g] 193–194°C; ir (KBr, v, cm⁻¹): 3472, 3394, 3296, 2940, 1613, 1586, 1545, 1445, 1373, 1322, 1210; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.18 (1H, dd, $J = 1.2$ Hz, $J = 1.6$ Hz, ArH), 7.48 (2H, d, $J = 8.0$ Hz, ArH), 7.39 (2H, q, $J = 6.8$ Hz, $J = 7.2$ Hz, ArH), 7.29 (3H, d, $J = 7.6$ Hz, ArH), 6.48 (2H, s, NH₂), 2.77 (4H, s, 2CH₂), 2.38 (3H, s, CH₃). Anal. Calcd. For C₁₉H₁₇N₃: C 79.41, H 5.96, N 14.62. Found: C 79.60, H 5.89, N 14.70.

4-(4-Methoxyphenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine (6b). This compound was obtained as yellow crystals, mp 186–187°C, Lit. [10g] 182–183°C; ir (KBr, v, cm⁻¹): 3467, 3287, 3178, 2940, 2830, 1609, 1578, 1547, 1510, 1453, 1405, 1374, 1322, 1302, 1277, 1251, 1214; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.18 (1H, dd, $J = 1.2$ Hz, $J = 1.6$ Hz, ArH), 7.56 (2H, d, $J = 8.4$ Hz, ArH), 7.39 (2H, q, $J = 6.0$ Hz, $J = 7.2$ Hz, ArH), 7.32 (1H, d, $J = 6.0$ Hz, ArH), 7.04 (2H, d, $J = 8.4$ Hz, ArH), 6.47 (2H, s, NH₂), 3.82 (3H, s, CH₃O), 2.78 (4H, d, $J = 3.2$ Hz, 2CH₂). Anal. Calcd. For C₁₉H₁₇N₃O: C 75.23, H 5.65, N 13.85. Found: C 75.42, H 5.69, N 13.79.

4-(3,4-Dimethoxyphenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine (6c). This compound was obtained as yellow crystals, mp 198–200°C, Lit. [10c] 203–204°C; ir (KBr, v, cm⁻¹): 3437, 3341, 3221, 2996, 2957, 1625, 1603, 1583, 1543, 1511, 1451, 1420, 1388, 1370, 1329, 1209; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.17 (1H, dd, $J = 1.2$ Hz, $J = 1.6$ Hz, ArH), 7.39 (2H, q, $J = 6.4$ Hz, $J = 7.2$ Hz, ArH), 7.29 (1H, d, $J = 6.4$ Hz, ArH), 7.18 (1H, s, ArH), 7.14 (1H, d, $J = 8.0$ Hz, ArH), 7.05 (1H, d, $J = 8.0$ Hz, ArH), 6.48 (2H, s, NH₂), 3.82 (3H, s, CH₃O), 3.79 (3H, s, CH₃O), 2.82 (2H, t, $J = 1.6$ Hz, $J = 4.0$ Hz, CH₂), 2.78 (2H, t, $J = 1.6$ Hz, $J = 4.0$ Hz, CH₂). Anal. Calcd. For C₂₀H₁₉N₃O₂: C 72.05, H 5.74, N 12.60. Found: C 72.21, H 5.69, N 12.71.

4-(4-Fluorophenyl)-5,6-dihydrobenzo[*h*]quinazolin-2-amine (6d). This compound was obtained as yellow crystals, mp 194–196°C; ir (KBr, v, cm⁻¹): 3489, 3302, 3175, 2946, 1627, 1604, 1553, 1499, 1452, 1413, 1398, 1373, 1321, 1297, 1222; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.18 (1H, dd, *J* = 1.2 Hz, *J* = 1.6 Hz, ArH), 7.64 (2H, dd, *J* = 5.6 Hz, *J* = 5.6 Hz, ArH), 7.40 (2H, q, *J* = 7.2 Hz, *J* = 8.0 Hz, ArH), 7.30 (3H, dd, *J* = 5.6 Hz, *J* = 8.0 Hz, ArH), 6.53 (2H, s, NH₂), 2.77 (4H, s, 2CH₂). Anal. Calcd. For C₁₈H₁₄FN₃: C 74.21, H 4.84, N 14.42. Found: C 74.35, H 4.82, N 14.46.

4-(4-Bromophenyl)-5,6-dihydrobenzo[*h*]quinazolin-2-amine (6e). This compound was obtained as yellow crystals, mp 228–230°C; ir (KBr, v, cm⁻¹): 3385, 3319, 3216, 2942, 1634, 1589, 1569, 1541, 1487, 1450, 1413, 1390, 1371, 1322, 1211; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.18 (1H, dd, *J* = 1.2 Hz, *J* = 1.6 Hz, ArH), 7.69 (2H, d, *J* = 8.4 Hz, ArH), 7.55 (2H, d, *J* = 8.4 Hz, ArH), 7.40 (2H, q, *J* = 6.8 Hz, *J* = 8.4 Hz, ArH), 7.30 (1H, d, *J* = 6.8 Hz, ArH), 6.56 (2H, s, NH₂), 2.77 (4H, s, 2CH₂). Anal. Calcd. For C₁₈H₁₄BrN₃: C 61.38, H 4.01, N 11.93. Found: C 61.50, H 4.03, N 11.90.

4-(4-Chlorophenyl)-5,6-dihydrobenzo[*h*]quinazolin-2-amine (6f). This compound was obtained as yellow crystals, mp 216–218°C, Lit. [10g] 222–223°C; ir (KBr, v, cm⁻¹): 3391, 3327, 3221, 2942, 1638, 1597, 1586, 1572, 1543, 1492, 1458, 1412, 1394, 1372, 1323, 1212; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.18 (1H, dd, *J* = 1.2 Hz, *J* = 1.6 Hz, ArH), 7.62 (2H, d, *J* = 8.4 Hz, ArH), 7.55 (2H, d, *J* = 8.4 Hz, ArH), 7.40 (2H, q, *J* = 6.0 Hz, *J* = 8.4 Hz, ArH), 7.30 (1H, d, *J* = 6.4 Hz, ArH), 6.56 (2H, s, NH₂), 2.77 (4H, s, 2CH₂). Anal. Calcd. For C₁₈H₁₄ClN₃: C 70.24, H 4.58, N 13.65. Found: C 70.43, H 4.50, N 13.58.

4-(3,4-Dichlorophenyl)-5,6-dihydrobenzo[*h*]quinazolin-2-amine (6g). This compound was obtained as yellow crystals, mp 210–212°C, Lit. [10c] 221–223°C; ir (KBr, v, cm⁻¹): 3485, 3297, 3183, 2934, 1622, 1564, 1544, 1492, 1470, 1450, 1410, 1386, 1365, 1350, 1317, 1298, 1247, 1212; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.18 (1H, d, *J* = 7.2 Hz, ArH), 7.84 (1H, d, *J* = 2.0 Hz, ArH), 7.56 (1H, d, *J* = 8.4 Hz, ArH), 7.58 (1H, dd, *J* = 2.0 Hz, *J* = 2.0 Hz, ArH), 7.40 (2H, q, *J* = 7.2 Hz, *J* = 8.0 Hz, ArH), 7.30 (1H, d, *J* = 7.2 Hz, ArH), 6.63 (2H, s, NH₂), 2.78 (4H, s, CH₂). Anal. Calcd. For C₁₈H₁₃Cl₂N₃: C 63.17, H 3.83, N 12.28. Found: C 63.40, H 3.76, N 12.21.

4-Phenyl-5,6-dihydrobenzo[*h*]quinazolin-2-amine (6h). This compound was obtained as yellow crystals, mp 164–165°C, Lit. [10h] 174–175°C; ir (KBr, v, cm⁻¹): 3387, 3321, 3214, 2936, 1634, 1606, 1585, 1544, 1495, 1451, 1440, 1411, 1373, 1384, 1322, 1208; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.18 (1H, dd, *J* = 1.2 Hz, *J* = 1.6 Hz, ArH), 7.57 (2H, dd, *J* = 1.6 Hz, *J* = 2.0 Hz, ArH), 7.47–7.52 (3H, m, ArH), 7.40 (2H, q, *J* = 5.6 Hz, *J* = 7.6 Hz, ArH), 6.51 (2H, s, NH₂), 2.77 (4H, s, CH₂). Anal. Calcd. For C₁₈H₁₅N₃: C 79.10, H 5.53, N 15.37. Found: C 79.33, H 5.48, N 15.25.

(E)-7-(4-Methylbenzylidene)-4-p-tolyl-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-2-amine (8a). This compound was obtained as yellow crystals, mp 229–230°C; ir (KBr, v, cm⁻¹): 3474, 3313, 3184, 2916, 1624, 1549, 1510, 1455, 1413, 1361, 1224, 1202; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.84 (2H, d, *J* = 8.0 Hz, ArH), 7.45 (2H, d, *J* = 8.0 Hz, ArH), 7.41 (1H, s, ArCH=), 7.31 (2H, d, *J* = 8.0 Hz, ArH), 7.24

(2H, *J* = 8.0 Hz, ArH), 6.51 (2H, s, NH₂), 3.12 (2H, d, *J* = 7.2 Hz, CH₂), 3.04 (2H, d, *J* = 4.0 Hz, CH₂), 2.37 (3H, s, CH₃), 2.33 (3H, s, CH₃). Anal. Calcd. For C₂₂H₂₁N₃: C 80.70, H 6.46, N 12.83. Found: C 80.86, H 6.48, N 12.80.

(E)-7-(4-Methoxybenzylidene)-4-(4-methoxyphenyl)-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-2-amine (8b). This compound was obtained as yellow crystals, mp 256–258°C; ir (KBr, v, cm⁻¹): 3475, 3370, 3217, 2934, 1624, 1606, 1582, 1542, 1510, 1460, 1440, 1399, 1366, 1308, 1248, 1220; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.94 (2H, d, *J* = 8.8 Hz, ArH), 7.53 (2H, d, *J* = 8.8 Hz, ArH), 7.39 (1H, s, ArCH=), 7.07 (2H, d, *J* = 8.8 Hz, ArH), 7.02 (2H, d, *J* = 8.8 Hz, ArH), 6.42 (2H, s, NH₂), 3.83 (3H, s, CH₃O), 3.80 (3H, s, CH₃O), 3.17 (2H, t, *J* = 6.4 Hz, CH₂), 3.06 (2H, t, *J* = 6.4 Hz, CH₂). Anal. Calcd. For C₂₂H₂₁N₃O₂: C 73.52, H 5.89, N 11.69. Found: C 73.38, H 5.91, N 11.73.

(E)-7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-2-amine (8c). This compound was obtained as yellow crystals, mp 187–189°C; ir (KBr, v, cm⁻¹): 3485, 3337, 3239, 3064, 2934, 1624, 1615, 1582, 1542, 1509, 1459, 1440, 1316, 1248, 1227; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.01(2H, dd, *J* = 5.6 Hz, *J* = 5.6 Hz, ArH), 7.63 (2H, dd, *J* = 5.6 Hz, *J* = 5.6 Hz, ArH), 7.43 (1H, s, ArCH=), 7.35 (2H, t, *J* = 8.8 Hz, ArH), 7.27 (2H, t, *J* = 8.8 Hz, ArH), 6.57 (2H, s, NH₂), 3.15 (2H, d, *J* = 7.2 Hz, CH₂), 3.08 (2H, t, *J* = 4.4 Hz, *J* = 4.4 Hz, CH₂). Anal. Calcd. For C₂₀H₁₅F₂N₃: C 71.63, H 4.51, N 12.53. Found: C 71.47, H 4.53, N 12.48.

(E)-7-(4-Chlorobenzylidene)-4-(4-chlorophenyl)-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-2-amine (8d). This compound was obtained as yellow crystals, mp 165–167°C; ir (KBr, v, cm⁻¹): 3483, 3323, 3192, 2928, 1672, 1623, 1594, 1544, 1492, 1460, 1407, 1361, 1295, 1225; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.97 (2H, d, *J* = 8.8 Hz, ArH), 7.62 (2H, d, *J* = 8.8 Hz, ArH), 7.58 (1H, s, ArCH=), 7.50 (2H, d, *J* = 8.8 Hz, ArH), 7.42 (2H, t, *J* = 8.8 Hz, ArH), 6.63 (2H, s, NH₂), 3.16 (2H, d, *J* = 6.8 Hz, CH₂), 3.09 (2H, t, *J* = 6.8 Hz, CH₂). Anal. Calcd. For C₂₀H₁₅Cl₂N₃: C 65.23, H 4.11, N 11.41. Found: C 65.48, H 4.13, N 11.37.

(E)-7-(3-Chlorobenzylidene)-4-(3-chlorophenyl)-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-2-amine (8e). This compound was obtained as yellow crystals, mp 135–137°C; ir (KBr, v, cm⁻¹): 3469, 3298, 3174, 2913, 1689, 1621, 1590, 1561, 1541, 1476, 1459, 1421, 1351, 1279, 1250, 1228, 1205; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.01 (2H, d, *J* = 7.6 Hz, ArH), 7.68 (2H, d, *J* = 6.8 Hz, ArH), 7.61 (1H, s, ArCH=), 7.54 (2H, d, *J* = 6.8 Hz, ArH), 7.40 (2H, d, *J* = 7.6 Hz, ArH), 6.67 (2H, s, NH₂), 3.18 (2H, t, *J* = 5.6 Hz, CH₂), 3.03 (2H, t, *J* = 5.6 Hz, CH₂). Anal. Calcd. For C₂₀H₁₅Cl₂N₃: C 65.23, H 4.11, N 11.41. Found: C 65.48, H 4.13, N 11.37.

(E)-7-(4-Bromobenzylidene)-4-(4-bromophenyl)-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-2-amine (8f). This compound was obtained as yellow crystals, mp 180–182°C; ir (KBr, v, cm⁻¹): 3454, 3293, 3170, 2956, 1672, 1620, 1588, 1488, 1459, 1403, 1351, 1176; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.95 (2H, d, *J* = 8.8 Hz, ArH), 7.70 (2H, d, *J* = 8.8 Hz, ArH), 7.66 (1H, s, ArCH=), 7.59 (2H, d, *J* = 8.8 Hz, ArH), 7.42 (2H, d, *J* = 8.8 Hz, ArH), 6.98 (2H, s, NH₂), 3.09 (2H, t, *J* = 5.6 Hz, CH₂), 2.88 (2H, t, *J* = 5.6 Hz, CH₂). Anal. Calcd. For C₂₀H₁₅Br₂N₃: C 52.54, H 3.31, N 9.19. Found: C 52.67, H 3.34, N 9.15.

4-p-Tolyl-5H-indeno[1,2-d]pyrimidin-2-amine (10a). This compound was obtained as yellow crystals, mp 199–200°C; ir (KBr, v, cm⁻¹): 3480, 3305, 3177, 2898, 1625, 1586, 1561, 1509, 1483, 1465, 1452, 1413, 1398, 1369, 1308, 1251; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.02 (2H, d, J = 8.0 Hz, ArH), 7.91 (1H, d, J = 7.6 Hz, ArH), 7.68 (1H, d, J = 7.2 Hz, ArH), 7.54 (1H, t, J = 7.2 Hz, ArH), 7.48 (1H, t, J = 7.2 Hz, ArH), 7.36 (2H, J = 8.0 Hz, ArH), 6.64 (2H, s, NH₂), 4.12 (2H, s, CH₂), 2.40 (3H, s, CH₃). Anal. Calcd. For C₁₈H₁₅N₃: C 79.10, H 5.53, N 15.37. Found: C 79.35, H 5.51, N 15.31.

4-(4-Methoxyphenyl)-5H-indeno[1,2-d]pyrimidin-2-amine (10b). This compound was obtained as yellow crystals, mp 206–208°C, Lit. [10f] 240–241°C; ir (KBr, v, cm⁻¹): 3312, 3178, 2887, 1643, 1608, 1591, 1567, 1533, 1510, 1481, 1466, 1438, 1422, 1395, 1370, 1301, 1255, 1209; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.11 (2H, d, J = 8.8 Hz, ArH), 7.94 (1H, d, J = 7.6 Hz, ArH), 7.68 (1H, d, J = 7.2 Hz, ArH), 7.54 (1H, t, J = 7.2 Hz, ArH), 7.48 (1H, t, J = 7.2 Hz, ArH), 7.11 (2H, J = 8.0 Hz, ArH), 6.60 (2H, s, NH₂), 4.12 (2H, s, CH₂), 3.85 (3H, s, CH₃O). Anal. Calcd. For C₁₈H₁₅N₃O: C 74.72, H 5.23, N 14.52. Found: C 74.58, H 5.30, N 14.61.

4-(3,4-Dimethoxyphenyl)-5H-indeno[1,2-d]pyrimidin-2-amine (10c). This compound was obtained as yellow crystals, mp 271–273°C; ir (KBr, v, cm⁻¹): 3405, 3310, 3189, 2962, 2935, 1640, 1604, 1542, 1511, 1484, 1463, 1449, 1423, 1401, 1378, 1326, 1250, 1235, 1211; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 7.91 (1H, d, J = 7.6 Hz, ArH), 7.68–7.72 (3H, m, ArH), 7.49–7.54 (2H, m, ArH), 7.12 (1H, d, J = 8.0 Hz, ArH), 6.60 (2H, s, NH₂), 4.15 (2H, s, CH₂), 3.88 (3H, s, CH₃O), 3.85 (3H, s, CH₃O). Anal. Calcd. For C₁₉H₁₇N₃O₂: C 71.46, H 5.37, N 13.16. Found: C 71.70, H 5.35, N 13.22.

4-(4-Fluorophenyl)-5H-indeno[1,2-d]pyrimidin-2-amine (10d). This compound was obtained as yellow crystals, mp 225–227°C; ir (KBr, v, cm⁻¹): 3482, 3306, 3176, 2890, 1632, 1588, 1566, 1509, 1488, 1463, 1449, 1419, 1394, 1372, 1300, 1279, 1253, 1222; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.17 (2H, dd, J = 5.6 Hz, J = 5.6 Hz, ArH), 7.92 (1H, d, J = 7.2 Hz, ArH), 7.68 (1H, d, J = 7.2 Hz, ArH), 7.54 (1H, t, J = 7.2 Hz, ArH), 7.49 (1H, t, J = 7.2 Hz, ArH), 7.38 (2H, t, J = 8.8 Hz, ArH), 6.70 (2H, s, NH₂), 4.13 (2H, s, CH₂). Anal. Calcd. For C₁₇H₁₂FN₃: C 73.63, H 4.36, N 15.15. Found: C 73.78, H 4.34, N 15.18.

4-(4-Chlorophenyl)-5H-indeno[1,2-d]pyrimidin-2-amine (10e). This compound was obtained as yellow crystals, mp 237–238°C, Lit. [10f] 245–246°C; ir (KBr, v, cm⁻¹): 3454, 3302, 3181, 1635, 1592, 1581, 1565, 1545, 1485, 1468, 1453, 1413, 1391, 1369, 1301, 1250, 1212; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.14 (2H, d, J = 8.8 Hz, ArH), 7.92 (1H, d, J = 7.2 Hz, ArH), 7.69 (1H, d, J = 7.2 Hz, ArH), 7.62 (2H, d, J = 8.4 Hz, ArH), 7.56 (1H, t, J = 7.2 Hz, ArH), 7.49 (1H, t, J = 7.2 Hz, ArH), 6.72 (2H, s, NH₂), 4.13 (2H, s, CH₂). Anal. Calcd. For C₁₇H₁₂CIN₃: C 69.51, H 4.12, N 14.30. Found: C 69.69, H 4.20, N 14.21.

4-(4-Bromophenyl)-5H-indeno[1,2-d]pyrimidin-2-amine (10f). This compound was obtained as yellow crystals, mp 233–234°C, Lit. [10f] 218–219°C; ir (KBr, v, cm⁻¹): 3455, 3302, 3182, 1634, 1591, 1579, 1562, 1547, 1486, 1468, 1452, 1409, 1388, 1366, 1300, 1251, 1212; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.07 (2H, d, J = 8.0 Hz, ArH), 7.92 (1H,

d, J = 7.6 Hz, ArH), 7.76 (2H, d, J = 8.4 Hz, ArH), 7.69 (1H, d, J = 7.6 Hz, ArH), 7.56 (1H, t, J = 7.2 Hz, J = 7.2 Hz, ArH), 7.50 (1H, t, J = 7.2 Hz, J = 7.2 Hz, ArH), 6.73 (2H, s, NH₂), 4.13 (2H, s, CH₂). Anal. Calcd. For C₁₇H₁₂BrN₃: C 60.37, H 3.58, N 12.42. Found: C 60.49, H 3.51, N 12.33.

4-(3,4-Dichlorophenyl)-5H-indeno[1,2-d]pyrimidin-2-amine (10g). This compound was obtained as yellow crystals, mp 232–233°C; ir (KBr, v, cm⁻¹): 3481, 3316, 3185, 2903, 1646, 1613, 1592, 1558, 1487, 1469, 1408, 1375, 1361, 1286, 1260, 1245, 1203; ¹H NMR (400MHz, DMSO-d₆) (δ , ppm): 8.33 (1H, d, J = 1.6 Hz, ArH), 8.09 (1H, dd, J = 1.6 Hz, J = 2.0 Hz, ArH), 7.93 (1H, d, J = 7.6 Hz, ArH), 7.81 (1H, d, J = 7.6 Hz, ArH), 7.70 (1H, d, J = 7.6 Hz, ArH), 7.56 (1H, t, J = 7.6 Hz, ArH), 7.52 (1H, t, J = 7.6 Hz, ArH), 6.80 (2H, s, NH₂), 4.16 (2H, s, CH₂). Anal. Calcd. For C₁₇H₁₁Cl₂N₃: C 62.21, H 3.38, N 12.80. Found: C 62.35, H 3.36, N 12.77.

Acknowledgments. This work was supported by the Natural Science Foundation of Jiangsu Education Department (No. 08KJB150017), Natural Science Foundation (06XLA09) of Xuzhou Normal University and PeiYu Foundation of Xuzhou Normal University (07PYL06).

REFERENCES AND NOTES

- [1] (a) Sasaki, T.; Minamoto, K.; Sujiki, T.; Yamashita, S. *Tetrahedron* 1980, 36, 865, and references cited therein; (b) Bradshaw, T. K.; Hutchinson, D. W. *Chem Soc Rev* 1977, 6, 43; (c) Marumoto, R.; Furukawa, Y. *Chem Pharm Bull* 1977, 25, 2974; (d) Cheng, C. C.; Roth, B. *Prog Med Chem* 1971, 8, 61; (e) Jones, S. A.; Sayers, J. R.; Walker, R. T.; Clereq, E. D. *J Med Chem* 1988, 31, 268.
- [2] (a) Dayam, R.; Grande, F.; Al-Mawsawi, L. Q.; Neamati, N. *Expert Opin Ther Patents* 2007, 17, 83, and references cited therein; (b) Klutchko, S. R.; Zhou, H.; Winters, R. T.; Tran, T. P.; Bridges, A. J.; Althaus, I. W.; Amato, D. M.; Elliott, W. L.; Ellis, P. A.; Meade, M. A.; Roberts, B. J.; Fry, D. W.; Gonzales, A. J.; Harvey, P. J.; Nelson, J. M.; Sherwood, V.; Han, H.-K.; Pace, G.; Smaill, J. B.; Denny, W. A.; Showalter, H. D. *H. D. J Med Chem* 2006, 49, 1475, and references cited therein; (c) Mazitschek, R.; Giannis, A. *Curr Opin Chem Biol* 2004, 8, 432.
- [3] (a) Ellsworth, E. L.; Tran, T. P.; Showalter, H. D.; Sanchez, J. P.; Watson, B. M.; Stier, M. A.; Domagala, J. M.; Gracheck, S. J.; Joannides, E. T.; Shapiro, M. A.; Dunham, S. A.; Hanna, D. L.; Huband, M. D.; Gage, J. W.; Bronstein, J. C.; Liu, J. Y.; Nguyen, D. Q.; Singh, R. *J Med. Chem.* 2006, 49, 6435; (b) Kunes, J.; Bazant, J.; Pour, M.; Waisser, K.; Slosarek, M.; Janota, J. *Farmaco* 2000, 55, 725.
- [4] (a) Herget, T.; Freitag, M.; Morbitzer, M.; Kupfer, R.; Stamminger, T.; Marschall, M. *Antimicrob Agents Chemother* 2004, 48, 4154; (b) Yang, H.; Kim, S.; Kim, M.; Reche, P. A.; Morehead, T. J.; Damon, I. K.; Welsh, R.-M.; Reinherz, E. L. *J Clin Invest* 2005, 115, 379.
- [5] Biological activities of quinazoline scaffold were well described and reviewed in: Vogtle, M. M.; Marzinzik, A. L. *QSAR Comb Sci* 2004, 23, 440.
- [6] Tanaka, T.; Toda, F. *Chem Rev* 2000, 100, 1025.
- [7] (a) Toda, F.; Takumi, H.; Yamaguchi, H. *Chem Exp* 1989, 4, 507; (b) Tanaka, K.; Kishigami, S.; Toda, F. *J Org Chem* 1991, 56, 4333; (c) Toda, F.; Tanaka, K.; Hamai, K. *J Chem Soc Perkin Trans 1* 1990, 3207; (d) Toda, F.; Suzuki, T.; Higa, S. *J Chem Soc Perkin Trans 1* 1998, 3521; (e) Toda, F.; Tanaka, K.; Iwata, S. *J Org Chem* 1989, 54, 3007.

- [8] (a) Kaupp, G.; Naimi-Jamal, M. R.; Schmeyers, J. *Tetrahedron* 2003, 59, 3753; (b) Zolfigol, M. A.; Safaiee, M. *Synlett* 2004, 5, 827; (c) Shaabani, A.; Bazgir, A.; Teimour, F. *Tetrahedron Lett* 2003, 44, 857.
- [9] (a) Rong, L. C.; Li, X. Y.; Wang, H. Y.; Shi, D. Q.; Tu, S. J. *Chem Lett* 2006, 35, 1314; (b) Rong, L. C.; Li, X. Y.; Wang, H. Y.; Shi, D. Q.; Tu, S. J.; Zhuang, Q. Y. *Synth Commun* 2007, 37, 183; (c) Rong, L. C.; Wang, H. Y.; Yang F.; Yao, H.; Li, X. Y.; Tu, S. J.; Shi, D. Q. *Lett Org Chem* 2007, 4, 296.
- [10] (a) Mishra, N.; Sen, M.; Nayak, A. *J Indian Chem Soc* 1990, 67, 353; (b) El-Rayyes, N. R.; Al-Saleh, B.; Al-Omrani, F. *J Chem Eng Data* 1987, 32, 280; (c) Deli, J.; Lorand, T.; Foldesi, A.; Szabo, D.; Prokai, L. *Acta Chim Hung* 1984, 117, 293; (d) Deli, J.; Lorand, T.; Szabo, D.; Foeldesi, A. *Pharmazie* 1984, 39, 539; (e) El-Rayyes, N. R.; Ramadan, H. M. *J Heterocyclic Chem* 1987, 24, 1141; (f) El-Rayyes, N.; Al-Qatami, S.; Edun, M. *J Chem Eng Data* 1987, 32, 481; (g) El-Rayyes, R. N.; Al-Saleh, B.; Al-Omrani, F. *J Chem Eng Data* 1987, 32, 280; (h) Wang, X. S.; Shi, D. Q.; Wang, S. H.; Tu, S. J. *Chin J Org Chem* 2003, 23, 1152.